Effects of COX1-2/5-LOX blockade in Alzheimer transgenic 3xTg-AD mice

• Published in: Inflammation research Vol. 66; no. 5; pp. 389 - 398
• Main Authors: Bitto, Alessandra, Giuliani, Daniela, Pallio, Giovanni, Irrera, Natasha, Vandini, Eleonora, Canalini, Fabrizio, Zaffe, Davide, Ottani, Alessandra, Minutoli, Letteria, Rinaldi, Mariagrazia, Guarini, Salvatore, Squadrito, Francesco, Altavilla, Domenica
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.05.2017; Springer Nature B.V
• Subjects: Allergology; Alzheimer Disease - drug therapy; Alzheimer Disease - metabolism; Amyloid beta-Protein Precursor - metabolism; Animals; Biomedical and Life Sciences; Biomedicine; Brain - drug effects; Brain - metabolism; Brain - pathology; Catechin - pharmacology; Catechin - therapeutic use; Cyclooxygenase Inhibitors - pharmacology; Cyclooxygenase Inhibitors - therapeutic use; Dermatology; Dinoprostone - metabolism; Disease Models, Animal; Drug Combinations; Immunology; Interleukin-1beta - metabolism; Leukotriene B4 - metabolism; Lipoxygenase Inhibitors - pharmacology; Lipoxygenase Inhibitors - therapeutic use; Male; Maze Learning - drug effects; Memory - drug effects; Mice, Transgenic; Neurology; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; NLR Family, Pyrin Domain-Containing 3 Protein - metabolism; Original Research Paper; Pharmacology/Toxicology; Rheumatology; tau Proteins - metabolism; NLRP3; Catechin; Neurodegeneration; Alzheimer; Memory; Baicalin

Objective and design Alzheimer’s disease (AD) is associated with amyloid plaques (Aβ) and hyperphosphorylated tau protein tangles in the brain. We investigated the possible neuroprotective role of flavocoxid, a dual inhibitor of cyclooxygenases-1/2 (COX-1/2) and 5-Lipoxygenase (5-LOX), in triple-tra...